Alzheimer’s and GLP-1s — the most exciting and most premature area of research
GLP-1 receptors are found throughout the brain. Preclinical evidence for neuroprotection is striking. Epidemiological signals are encouraging. The definitive trials are still running.
Sleep apnoea and GLP-1s — the SURMOUNT-OSA data and what it means for SA patients
Tirzepatide reduced sleep apnoea severity by up to 63% in the SURMOUNT-OSA trial — a result comparable in magnitude to CPAP therapy. Here is what this means in an SA context.
How GLP-1s actually work — no jargon, no hype
Your gut has been signalling to your brain for millions of years. GLP-1 medications borrowed that pathway — and the results have stunned researchers.
Beyond weight loss: the conditions GLP-1s are quietly transforming
Heart disease. Kidney disease. Sleep apnoea. Even Alzheimer’s. The indications pipeline is expanding fast — and most patients don’t know it.
Semaglutide vs tirzepatide vs dulaglutide — what actually changes between them
They all target GLP-1 receptors. But the mechanisms, results and side effect profiles diverge in ways that matter enormously for individual patients.
Why some people respond dramatically and others barely at all — the genetics behind GLP-1 response
In the STEP 1 trial, the top responders lost nearly 25% of body weight. The bottom 25% lost less than 5%. The drug was identical. So what was different?
What the clinical trials actually showed — vs what the headlines said
The STEP trials are among the most cited studies in modern medicine. Here is what they measured, what they did not, and where the media coverage went wrong.
The cardiovascular outcomes data — what the SELECT trial actually proved
A 20% reduction in major cardiovascular events. Over 17,000 patients. Without any diabetes. The SELECT trial may be the most important GLP-1 finding since the weight loss data.
GLP-1s and PCOS — the evidence, the off-label reality and the patient demand
PCOS affects roughly 10% of women of reproductive age and has significant metabolic overlap with the conditions GLP-1s treat well. Off-label prescribing is widespread. The evidence is growing.